CYTK CYTOKINETICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1061983 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY29.9%
TTM net income YoY-3.5%
TTM EPS YoY4.4%
Revenue 3-yr CAGR143.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-625.2%
Net margin-686.6%
FCF margin-519.5%
EBITDA margin-613.2%
Returns
ROE—
ROA-47.7%
ROIC (approx.)—
Asset turnover0.07x
Leverage & solvency
Liabilities / assets117.6%
Debt / equity—
Current ratio3.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue14.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $88.04M | $18.47M |
| R&D expense | $416.03M | $339.41M |
| SG&A expense | $284.27M | $215.31M |
| Operating income | -$612.26M | -$536.25M |
| Interest expense | $45.58M | $37.70M |
| Income tax | $0 | $0 |
| Net income | -$784.96M | -$589.53M |
| EBITDA | -$602.13M | -$526.72M |
| EPS (basic) | -6.54 | -5.26 |
| EPS (diluted) | -6.54 | -5.26 |
| Weighted avg. shares (diluted) | 120,103 | 111,979 |
| Balance sheet | ||
| Cash & equivalents | $122.52M | $94.86M |
| Short-term investments | $759.70M | $981.16M |
| Receivables | $17.76M | $16.65M |
| Inventory | $0 | — |
| Current assets | $916.98M | $1.11B |
| PP&E, net | $79.19M | $65.81M |
| Total assets | $1.42B | $1.40B |
| Current liabilities | $202.45M | $179.67M |
| Short-term debt | $41.18M | $11.52M |
| Long-term debt | $246.38M | $93.23M |
| Total debt | $287.56M | $104.75M |
| Total liabilities | $2.08B | $1.54B |
| Shareholders' equity | -$659.62M | -$135.37M |
| Net debt | $165.05M | $9.89M |
| Shares outstanding | 122.94M | 118.21M |
| Cash flow statement | ||
| Operating cash flow | -$510.01M | -$395.89M |
| Capital expenditure | $24.81M | $3.91M |
| Free cash flow | -$534.82M | -$399.80M |
| Investing cash flow | $16.67M | -$553.10M |
| Financing cash flow | $524.46M | $930.61M |
| Depreciation & amortization | $10.12M | $9.53M |
| Stock-based compensation | $112.29M | $97.84M |
Free plan shows the latest 2 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.